Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.67 |
| ▸ | MEN1 | O00255 | 6/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18118631 | 0.80 | DHODH (0.67) | DHODHKMT2AMEN1NPC1ALDH1A1 | |
| SCHEMBL5223456 | 0.78 | MEN1 (0.78) | DHODHKMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL30236587 | 0.78 | MEN1 (0.78) | DHODHKMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL18585743 | 0.78 | DHODH (0.64) | DHODHKMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL10520787 | 0.78 | KMT2A (0.66) | DHODHKMT2AMEN1LMNAL3MBTL1 | |
| SCHEMBL27602570 | 0.77 | TSHR (0.68) | DHODHKMT2AMEN1LMNAL3MBTL1 | |
| SCHEMBL31665319 | 0.77 | KMT2A (0.66) | DHODHKMT2AMEN1LMNAL3MBTL1 | |
| SCHEMBL3456470 | 0.77 | NPC1 (1.00) | DHODHKMT2AMEN1LMNAL3MBTL1 | |
| SCHEMBL7161734 | 0.76 | KMT2A (0.63) | DHODHKMT2AMEN1LMNAL3MBTL1 | |
| SCHEMBL5668753 | 0.75 | P2RX1 (0.84) | DHODHKMT2AMEN1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160287549-A1 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | GENZYME CORPORATION | 2016-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287549-A1 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | DHODH, DLD, HAGH | DHODH 1/4885KMT2A 1965/4885MEN1 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.